The core problem the authors identify is temporal. Huntington’s disease is caused by expanded CAG repeats in the HTT gene on chromosome 4p16.3, and its prodromal phase, the long silent stretch before formal diagnosis, often spans more than a decade. During this period and after clinical onset, symptoms emerge in a non-linear fashion, with motor, cognitive, and psychiatric manifestations fluctuating over short time scales. The standard instruments used to assess the disease, including the Unified Huntington’s Disease Rating Scale and its composite version, the cUHDRS, are deployed episodically during clinic visits. They capture a snapshot, not the film. In early stages of the disease, where changes are subtle and variable, these episodic assessments can obscure the very treatment effects that clinical trials are designed to detect, potentially masking the benefit of investigational drugs and inflating the size, cost, and duration of studies.

The review situates digital health technologies as a complement to existing clinical research outcomes and patient reported outcomes rather than a replacement. Fluid biomarkers such as mutant huntingtin protein and neurofilament light chain measured in cerebrospinal fluid, and more recently in serum, correlate with symptoms and show promise, as do emerging assays based on deregulated phosphatidylcholine metabolism and advanced imaging modalities including MRI, PET, and functional MRI. But these measures are invasive, expensive, or episodic in their own right. What digital technologies offer is the possibility of high-frequency, longitudinal tracking of motor and cognitive function at scale, in the patient’s natural environment, without the friction of repeated clinic visits.

A concrete proof of concept already exists. The Huntington’s Disease Digital Motor Score, developed by Roche Diagnostics on a smartphone platform, represents a natural extension of physician-based episodic monitoring, translating structured motor tasks into quantitative data that can detect progression with greater sensitivity than traditional scales alone. The review also points to a broader ecosystem of digital tools matured in adjacent neurodegenerative diseases, including multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease, where wearable sensors, gait measurement devices, and tablet-based assessments have been deployed with increasing sophistication. The COVID-19 pandemic accelerated the incorporation of telemedicine and remote patient reported outcomes, demonstrating that decentralized assessment is feasible even in populations with complex neurological burdens.

Yet the authors are candid about the limitations of active digital tools. Wearable devices and smartphone applications impose a burden on users, and adherence tends to decline significantly over time, undermining their utility in the long-term studies that neurodegenerative disease research demands. This is where the concept of the digital exhaust becomes central. Rather than asking patients to perform tasks, the vision is to extract clinically meaningful signals from the data people generate simply by living: the accelerometer readings from a wrist-worn device, the rhythm of keystrokes on a keyboard, the acoustic signatures of speech captured by smartphone microphones, sleep patterns derived from device sensors, and even patterns of web and social media activity that may correlate with apathy, depression, and anxiety.

The technical palette the review assembles is strikingly broad. Inertial measurement units in consumer wearables can detect movement anomalies. Smartphone and computer interactions can yield vocal features such as pitch frequency, jitter, and shimmer, which have been shown in prior research to help classify Huntington’s disease using acoustic and lexical features. Ocular analysis through digital cameras can monitor saccades, rapid eye movements whose latency and inhibition are altered in both manifest and premanifest disease. Optical coherence tomography, a benchtop instrument already ubiquitous in optometry offices, can detect retinal biomarkers associated with neurodegeneration. The authors even suggest that non-traditional service providers such as optometrists and dentists could eventually participate in screening and early diagnosis, expanding the diagnostic funnel far beyond the neurology clinic.

Perhaps the most futuristic element of the proposal involves the home itself. The authors envision fully passive residential monitoring built on the Internet of Medical Things, where ambient sensors gather rich data with very high frequency and zero patient burden. They point to passive radio-frequency sensing, already piloted with some success in Parkinson’s disease, which can capture features derived from motion, breathing, and sleep staging and correlate them with activities of daily living. Technologies borrowed from home security and automotive safety, including millimeter-wave radar, infrared motion detection, ultrasonic reflection, and echolocation-inspired systems, could detect room occupancy, falls, and movement patterns. These platforms are well suited to home health monitoring because their waveforms penetrate structural features, function nocturnally, and tolerate challenging environments such as steam and humidity. A collaboration between the home security industry and health technology developers, the authors argue, could be fertile ground for innovation, potentially accelerated through demonstration projects in assisted living facilities.

On the biochemical front, the review highlights emerging non-invasive biomarkers that could eventually be packaged into consumer-grade assay kits, much as flow-based COVID-19 tests popularized at-home diagnostics. Salivary levels of total huntingtin protein have been found to be elevated in Huntington’s disease patients, and salivary interleukin-6, but not plasma levels, correlates with clinical metrics. Mutant huntingtin protein has also been detected at high levels in tear fluid. These analytes, combined with the digital exhaust of daily living, could form a multi-modal picture of disease state that is both biologically grounded and behaviorally rich.

The authors organize the potential data streams around four major symptom domains. Gross and fine motor performance would draw on activity-tracking wearables, ambient monitoring, active keyboard and ocular tests, and passive motion and keystroke capture. Cognitive function, including executive function, memory recall, and processing speed, could be probed through gamified challenges on digital devices. Quality of life and psychiatric measures, including apathy and anxiety, could be inferred from combinations of web activity, sleep metrics, activity profiles, and social media interaction. Speech and acoustic function would be assessed through altered prosody, intonation, and phonation captured during ordinary computer and smartphone use. Recent research on passive smartphone sensors suggests that psychopathological markers such as internalization, detachment, disinhibition, antagonism, and thought disorder can be derived from GPS and IMU data combined with device activity logs, hinting at the depth of insight available from devices people already carry.

The authors liken the resulting composite record to on-board diagnostics in automobiles or flight data recorders in aircraft: continuous, passive documentation of the patient’s state between scheduled service intervals. Smart residential video devices, including televisions and computers with large graphical interfaces, could overcome the ergonomic limitations of smartphones, offering gamified symptom assessments, informational content, and two-way communication with health providers. The result, if realized, would be a real-world portrait of daily living that complements interval-based clinical assessment and gives drug developers the statistical power to detect treatment effects earlier, with smaller cohorts and shorter trials.

None of this happens without coordination, and the review closes with a concrete call to action. The authors urge convening dialogue among pharmaceutical industry delegates, Huntington’s disease experts, research foundations such as CHDI, professional medical societies, and digital health technology developers. They call on integrators such as the Critical Path Institute, which has made notable inroads deploying digital approaches in Parkinson’s disease, to engage health authorities on the design of composite measures and endpoints. They propose incentivizing data sharing and federated learning consortia through funding mechanisms such as the Innovative Health Initiative and the US National Institutes of Health, reimagining established endpoints like the cUHDRS to benefit from digital monitoring, and convening working groups to design interoperability standards. Existing frameworks such as Fast Healthcare Interoperability Resources and Health Level Seven address many technical issues, but integration with electronic health records will require careful alignment with region-specific data protection regimes including the General Data Protection Regulation and the Health Insurance Portability and Accountability Act.

The stakes are considerable. Huntington’s disease affects roughly one in ten thousand people, with higher prevalence in persons of Caucasian descent, and it is fatal, with a median post-diagnosis survival of just fifteen years. As a Mendelian disorder, its pathogenesis is molecular rather than environmental, and children of affected parents face a fifty percent probability of inheritance, making early detection and accurate progression tracking uniquely consequential for this population. The authors argue that once disease-modifying treatments become available, digital monitoring would enable a shift to the left, identifying and treating patients at the earliest stages of disease with precision that episodic clinic visits cannot match. Given the ethical, economic, and societal burden of neurodegenerative disease, they conclude, capturing the digital exhaust of daily life may prove to be one of the most consequential untapped resources in modern medicine.

Subject of Research: AI-inspired passive digital monitoring for tracking Huntington's disease progression in drug development

Article Title: The potential of AI inspired approaches for patient monitoring in drug development for Huntington’s disease: capturing the digital exhaust for activities of daily living

Article References: The potential of AI inspired approaches for patient monitoring in drug development for Huntington’s disease: capturing the digital exhaust for activities of daily living. (n.d.). https://doi.org/10.3389/fmmed.2026.1966010

Image Credits: AI Generated

DOI: 10.3389/fmmed.2026.1966010

Keywords: Huntington's disease, artificial intelligence, digital biomarkers, passive monitoring, digital health technology, drug development, neurodegeneration, wearable sensors, Internet of Medical Things, activities of daily living, clinical trials, UHDRS

The research team set out to test curcumin against the major molecular disturbances that characterize Huntington’s disease pathogenesis: disrupted protein homeostasis, impaired mitochondrial function, oxidative stress, altered epigenetic regulation, endoplasmic reticulum stress and inflammatory signalling. Rather than focusing on a single readout, the investigators used established HD cellular models to profile the compound’s effects across these interconnected processes, an approach that reflects the growing recognition that mutant huntingtin toxicity is not confined to one cellular compartment or pathway.

One of the central findings concerns protein aggregation, a hallmark of the disease. The mutant huntingtin protein tends to misfold and clump into aggregates that burden the cell’s quality-control machinery. In the HD cells treated with curcumin, the researchers observed a reduction in mutant huntingtin aggregation. The mechanism behind this effect appears to involve autophagy, the cellular recycling system that engulfs and degrades damaged proteins and organelles. Curcumin treatment elevated autophagic clearance, giving cells a more efficient route for disposing of the aggregation-prone protein species that accumulate in the disease state.

The study also documented a striking effect on the unfolded protein response. In HD cells, curcumin reduced PERK-eIF2α signalling, a branch of the endoplasmic reticulum stress pathway that becomes chronically activated when misfolded proteins overwhelm the folding capacity of the ER. Persistent PERK-eIF2α signalling is thought to contribute to neuronal dysfunction by throttling protein synthesis and amplifying stress responses, so its attenuation by curcumin suggests that the compound helps relieve one of the key proteostasis pressures exerted by mutant huntingtin.

Mitochondrial energetics emerged as another pathway responsive to the polyphenol. Cells carrying mutant huntingtin typically show depleted ATP levels and impaired expression of genes that govern mitochondrial biogenesis and antioxidant defense. In the curcumin-treated HD cells, ATP levels increased, and the expression of Ppargc1α and Nrf1, transcriptional regulators of mitochondrial function and oxidative stress responses, was partially restored. These shifts indicate that curcumin does not merely mop up reactive molecules downstream but may help re-establish portions of the transcriptional program that keeps mitochondria functional in vulnerable neurons.

Consistent with that mitochondrial rescue, curcumin treatment reduced both mitochondrial and cytosolic reactive oxygen species. Oxidative stress is a pervasive feature of Huntington’s disease, damaging lipids, proteins and DNA and feeding forward into further mitochondrial dysfunction. By lowering reactive oxygen species in two cellular compartments simultaneously, curcumin appears to interrupt this self-reinforcing loop, complementing its effects on ATP production and mitochondrial gene expression.

Beyond proteostasis and energetics, the study reached into epigenetic territory. The researchers found that curcumin reduced H3K27 trimethylation, a histone modification laid down by the polycomb repressive complex 2 that is dysregulated in Huntington’s disease. Huntingtin itself has been shown to facilitate PRC2 function, and aberrant histone methylation patterns are thought to contribute to the transcriptional dysregulation seen in affected neurons. The observation that a small dietary polyphenol can shift this epigenetic mark in HD cells adds a mechanistic dimension to curcumin’s profile that goes well beyond its conventional description as an antioxidant.

Perhaps the most clinically resonant result came from experiments using lymphoblastoid cell lines derived from Huntington’s disease patients. In these human cells, curcumin treatment abrogated inflammatory responses. Immune activation is now recognized as an early and progressive feature of the disease, detectable even before clinical onset, and mutant huntingtin fragmentation in immune cells has been shown to track disease progression. The finding that curcumin can suppress inflammatory signalling in patient-derived cells suggests that the compound’s anti-inflammatory reputation, documented extensively in other disease contexts, extends to the peripheral immune dimension of Huntington’s disease as well.

The authors are careful to frame curcumin as an exploratory pharmacological tool rather than a ready-made therapy, and that framing matters. Curcumin’s notoriously poor bioavailability has limited clinical translation across many candidate diseases, and the present work was conducted entirely in cellular models, which cannot capture the full complexity of a progressing neurodegenerative disorder in the living brain. Nevertheless, the breadth of the observed effects is notable. A single compound that reduces mutant huntingtin aggregation, dampens ER stress, boosts autophagic clearance, restores mitochondrial ATP and gene expression, lowers reactive oxygen species in two compartments, modulates an epigenetic mark and silences inflammatory responses in patient-derived cells provides researchers with a versatile probe for dissecting which of these pathways are causally linked in mHTT toxicity.

That probe function may prove to be the study’s most durable contribution. Huntington’s disease drug development has faced significant setbacks in recent years, including disappointing results for antisense oligonucleotide trials, and the field continues to explore complementary strategies ranging from gene therapy to stem cell approaches. Against that backdrop, a well-characterized polyphenol that touches multiple validated disease pathways in parallel offers both a research instrument and a starting point for medicinal chemistry. If future studies can identify which of curcumin’s many molecular actions are most responsible for its benefits in these models, and whether improved analogues with better drug-like properties can reproduce those effects, the humble turmeric compound may yet contribute something concrete to the long effort to slow a disease that currently has no cure.

Subject of Research: Effects of curcumin on dysregulated molecular pathways in cellular models of Huntington's disease

Article Title: Evaluation of curcumin as an exploratory pharmacological tool for modulating dysregulated molecular pathways in cellular models of Huntington’s disease

Article References: Singh, S., Mehta, R., Dabhi, R., Shah, A., Bhatt, V., Purushottam, M., Sud, R., Viswanath, B., & Vijayvargia, R. (2026). Evaluation of curcumin as an exploratory pharmacological tool for modulating dysregulated molecular pathways in cellular models of Huntington’s disease. Molecular Biology Reports, 53(1), Article 1557. https://doi.org/10.1007/s11033-026-12739-1

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12739-1

Keywords: Huntington's disease, curcumin, mutant huntingtin, autophagy, mitochondrial dysfunction, oxidative stress, endoplasmic reticulum stress, epigenetics, inflammation, neurodegeneration, polyphenol, cellular models

The team’s starting point was a systematic survey of how the human striatum changes with age. Rather than focusing narrowly on the canonical disease genes, the researchers examined global patterns of gene expression in human striatal tissue and found something striking: an age-dependent upregulation of translation-related genes, the molecular machinery that ribosomes use to build proteins from messenger RNA templates. Among the genes climbing with age was PPP1R15B, abbreviated R15B, a regulator of protein synthesis that belongs to a conserved family of stress-responsive translation controllers. In other words, one of the deepest molecular signatures of an aging striatum is a gradual turning up of the dial that governs how much protein cells make—a change that, in a brain already burdened with a misfolding-prone mutant protein, could be far from benign.

The logic of why this matters comes down to proteostasis, the cell’s tightly balanced system for producing, folding, and clearing proteins. Neurons are among the longest-lived cells in the body and cannot dilute toxic protein clumps by cell division, so they depend exquisitely on keeping protein synthesis under control. Mutant huntingtin is known to disrupt this balance, and recent work from other groups has implicated polyglutamine-mediated ribotoxicity—stress inflicted on the protein-making machinery itself—in Huntington’s pathology. The new findings place R15B squarely in this arena. As its expression rises with age in the striatum, the cell’s capacity to rein in translation may erode, allowing the mutant protein and the stress it generates to accumulate past a tipping point. Aging, in this view, is not just the passage of time but an active physiological process that remodels the disease landscape.

To test whether R15B is merely a bystander or an active participant, the researchers turned to pharmacology. Raphin1, a selective inhibitor of R15B developed through earlier work on translation-control pathways, was administered to HD YAC128 mice, a widely used model that carries the human mutant HTT gene. The results were notable on two fronts: the compound rescued early learning deficits and also alleviated late-stage motor impairments in the animals. That dual rescue spans both cognitive and motor domains of the disease, suggesting that dampening excessive protein synthesis can meaningfully alter functional outcomes in a living organism carrying the Huntington’s mutation, not merely in isolated cells.

The cellular centerpiece of the study is a reprogramming technology that has become one of the most powerful tools in human neurodegeneration research. The team took skin fibroblasts from symptomatic Huntington’s disease patients and directly converted them into striatal medium spiny neurons, the very cell type that degenerates in patients. This approach, often called direct neuronal reprogramming, bypasses stem cells and preserves age-associated signatures of the donor cells, which is critical for a disease whose onset is so tightly linked to aging. These patient-derived HD-MSNs displayed aberrant translation patterns along their neurites, the long processes that neurons use to communicate—evidence that the protein-synthesis defect is not a diffuse, whole-cell phenomenon but one that strikes at the subcellular compartments where neuronal health is maintained.

When the researchers treated these patient-derived neurons with Raphin1, the effects cascaded across nearly every measure of disease biology they examined. The aberrant translation phenotype along the neurites was reduced, as were the burdens of mutant HTT aggregates—the characteristic protein clumps that define the disorder. The drug also ameliorated disease-associated transcriptional changes, indicating that correcting the translation defect reaches upstream into gene expression programs that have gone awry. Most importantly, Raphin1 prevented neuronal death, the endpoint that matters most for any future therapy. The genetic experiments reinforced the pharmacological ones: knocking down R15B protected the HD-MSNs, while overexpressing it made the disease phenotypes worse. That dose-dependent relationship—less R15B is protective, more R15B is harmful—is exactly the pattern one would expect if R15B is a genuine driver of the disease process rather than a correlate.

The second half of the story adds a layer of regulatory elegance. The researchers found that miR-196a, a microRNA that directly targets human R15B messenger RNA and suppresses its translation, declines in an age-dependent manner in both the human striatum and the reprogrammed medium spiny neurons. MicroRNAs are short regulatory RNAs that fine-tune gene expression after transcription, and their gradual loss with age is an emerging theme in the biology of aging tissues. Here, the declining miR-196a provides a mechanistic explanation for the rising R15B: as the brake on R15B production is released over the decades, protein synthesis regulation drifts, and the vulnerable striatal neurons lose another layer of protection against the mutant protein. The two arms of the study—aging-driven upregulation of R15B and age-dependent loss of its microRNA brake—converge on the same node from opposite directions.

That convergence immediately suggests a therapeutic strategy, and the team tested it. When they overexpressed miR-196a in the disease models, levels of mutant HTT aggregation dropped. Restoring a single age-eroded microRNA was sufficient to reduce the accumulation of the toxic protein species at the heart of the disease. The miR-196a–R15B axis thus emerges as a coherent regulatory circuit: a microRNA that restrains a translation regulator, whose age-related weakening permits the proteostasis failures that characterize Huntington’s disease. Because the axis was validated across diverse models—human postmortem striatal tissue, a transgenic mouse model, and patient-derived reprogrammed neurons—and across diverse phenotypes, from translation patterns to aggregation to cell survival, it stands on unusually broad evidentiary footing for a newly identified disease modifier.

The implications reach beyond Huntington’s disease itself. Huntington’s is one of several adult-onset polyglutamine disorders, and the broader principle—that age-dependent changes in translation control can act as disease modifiers in the vulnerable neurons of the aging brain—may apply to other neurodegenerative conditions in which protein misfolding accumulates over decades. The study also highlights the strategic value of directly reprogrammed patient neurons, which retain the aging biology that conventional stem-cell-derived models often erase. For a field that has endured repeated disappointments in clinical trials, including setbacks for antisense approaches targeting mutant HTT itself, the identification of a druggable modifier downstream of the mutation offers a complementary path: rather than attacking the mutant gene directly, one can target the cellular vulnerabilities that determine when and how severely the mutation strikes.

Considerable work remains before these findings translate to patients. Raphin1’s rescue was demonstrated in mice, and the safety, pharmacokinetics, and delivery of R15B inhibition or miR-196a restoration in humans are open questions. The published version of the study, which appeared online on 26 September 2026 as a peer-reviewed accepted manuscript, will be subject to further editorial refinement. But the conceptual advance is clear and consequential. Huntington’s disease has always carried its trigger from birth, yet its devastation unfolds on a clock set by aging. By identifying a PPP1R15B–miR-196a node where that clock is read out in the striatum—and by showing that intervening at that node rescues deficits in animals and protects patient-derived neurons—the researchers have converted a decades-old mystery about disease onset into a concrete, testable target. In the search for the first disease-modifying therapy for Huntington’s disease, the age-dependent biology of protein synthesis has just moved to the top of the list of places to look.

Subject of Research: Age-dependent translation regulation via the PPP1R15B–miR-196a axis as a modifier of Huntington's disease

Article Title: Age-dependent alterations in human striatum identify a PPP1R15B-miR-196a node as a modifier of Huntington’s disease

Article References: Church, V. A., Krzyzosiak, A., Miao, B., Chen, S., Walker, C. K., Kwon, J.-S., Dahiya, S. L., Wang, L., Al-Dalahmah, O., Zhang, B., Victor, M. B., Bertolotti, A., & Yoo, A. S. (2026). Age-dependent alterations in human striatum identify a PPP1R15B-miR-196a node as a modifier of Huntington’s disease. Nature Communications. https://doi.org/10.1038/s41467-026-78010-0

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78010-0

Keywords: Huntington's disease, striatum, PPP1R15B, miR-196a, translation regulation, proteostasis, neurodegeneration, aging, Raphin1, medium spiny neurons, direct neuronal reprogramming, mutant huntingtin

At the center of the experimental effort is Randal Halfmann, Ph.D., an Investigator at the Stowers Institute for Medical Research in Kansas City, whose laboratory has been selected to generate the project’s large-scale data on protein aggregation. His lab will receive approximately $4.1 million over two years as part of the initiative, which is called NATIVE-ID and is led by the Innovative Genomics Institute at the University of California, Berkeley. The work falls under ARPA-H’s BIOGAMI program, a broader effort to understand and ultimately control harmful protein aggregation, led by ARPA-H Program Manager Shannon Greene, Ph.D. Halfmann’s role is to supply the raw experimental fuel that the rest of the team will convert into predictive models.

The reason such a massive data-generating effort is needed lies in a fundamental blind spot in modern computational biology. Artificial intelligence has transformed scientists’ ability to predict the three-dimensional structures of many proteins, but roughly one-third of all proteins lack a stable structure altogether. These molecules, known as intrinsically disordered proteins, or IDPs, do not hold a single fixed shape. Instead, they shift among many conformations, and in doing so they can become entangled in harmful clumping, a process called aggregation that is closely associated with neurodegenerative disease. For AI systems trained largely on well-ordered structures, reading the behavior of these shape-shifting proteins remains an enormous challenge.

Halfmann believes the payoff for cracking that challenge could be transformative. Treatments for neurodegenerative diseases remain extremely limited, and most interventions arrive only after symptoms appear. If researchers could predict the probabilities and onset ages of disease from a person’s protein sequences, he argues, far more people could seek preventive or early-stage treatments or enroll in clinical trials before irreversible damage occurs. He has even proposed a more futuristic application: designing therapeutic IDPs that could intercept the problematic interactions driving diseases like Alzheimer’s, essentially fighting disordered proteins with engineered ones.

The key insight underlying the project is that even without a fixed structure, the behavior of an IDP is still governed by its amino-acid sequence. Small changes in that sequence can tip a protein between remaining soluble and beginning to clump. Halfmann’s lab will conduct large-scale experiments in yeast cells to test how sequence variations affect this balance, building on prior studies demonstrating that disease-relevant protein behavior observed in yeast can reliably inform how those same proteins behave in human cells. The workhorse technology is Distributed Amphifluoric FRET, or DAmFRET, a method his team developed in 2018 that measures protein self-assembly inside individual living cells.

The scale of the planned measurements is what sets this effort apart. Halfmann’s team will measure the aggregation tendencies of 50,000 proteins, each expressed individually in yeast cells under diverse conditions designed to mimic the cellular mishaps that accumulate as humans age. Across more than one million samples, the team expects to produce more than 10 billion individual measurements of protein aggregation. Direct measurements of protein aggregation at cellular resolution have not previously been done at anything approaching this scale, according to Halfmann, who noted that his laboratory has been laying the foundation for this moment since he joined Stowers in 2015.

That foundation includes a landmark achievement. In 2023, Halfmann’s lab became the first to experimentally determine the structure of the initiating step in amyloid formation associated with Huntington’s disease, work that involved the polyglutamine proteins implicated in that disorder. If scientists can figure out exactly how aggregation starts, Halfmann has argued, they can potentially stop the forest fire before it ignites. His lab has also studied TDP-43, a protein strongly associated with ALS and frontotemporal lobar degeneration. Those earlier studies, which examined hundreds of protein sequences, served as pilots for the new undertaking, which will scale the approach to 50,000 sequences.

The initial focus of NATIVE-ID is frontotemporal lobar degeneration, or FTLD, a neurodegenerative disease that shares significant genetic and biological features with ALS. The larger ambition, however, is to develop approaches that generalize across other diseases involving protein misfolding. The team’s other members bring complementary capabilities: generating human neurons from different genetic backgrounds, measuring protein interactions inside those neurons, developing advanced deep-learning frameworks, determining protein structures in test tubes, and running large-scale computational simulations of protein behavior. In addition to Halfmann, the collaboration includes scientists from UC Berkeley, Brown University, Emory University, Johns Hopkins University, Parallel Squared Technology Institute and Texas A&M University, with the Innovative Genomics Institute effort led by Executive Director Brad Ringeisen and Hanqin Li, head of the institute’s Advanced Translational Genetics lab.

Leadership at Stowers emphasizes that the experimental and computational halves of the project are inseparable. Alejandro Sánchez Alvarado, Ph.D., President and Chief Scientific Officer of the institute, noted that a deep learning model capable of decoding the language of disordered proteins needs rigorously obtained data at scale, something that has yet to exist. Halfmann’s laboratory, he said, will provide what has been missing: more than 10 billion measurements of aggregation, taken one living cell at a time, across 50,000 proteins, while colleagues at the Innovative Genomics Institute supply the human neurons in which the model’s predictions must ultimately hold true. Neither half of the project, he argued, can succeed without the other.

The award funds an initial two-year phase of work, structured within BIOGAMI as the first of two 24-month phases. Phase 1 is dedicated to delivering foundational datasets and models; Phase 2 will focus on validating potential therapeutics and on new ways to detect protein dysfunction earlier in the course of disease. For Halfmann, the timing is critical. Artificial intelligence now stands a real chance of decoding the language of intrinsically disordered proteins, he said, but only if it is provided sufficient high-quality data, and DAmFRET has finally matured enough to generate that data. If the collaboration succeeds, the earliest molecular whispers of Alzheimer’s, ALS and related diseases may one day be readable, and interceptable, years before the first symptom appears.

Subject of Research: AI prediction of intrinsically disordered protein aggregation in neurodegenerative disease

Article Title: Stowers scientist selected for $28.6 million effort to predict protein changes behind neurodegenerative disease

Article References: Stowers scientist selected for $28.6 million effort to predict protein changes behind neurodegenerative disease. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: protein aggregation, intrinsically disordered proteins, neurodegenerative disease, artificial intelligence, ARPA-H, DAmFRET, ALS, Huntington's disease, frontotemporal lobar degeneration, deep learning, Stowers Institute, protein misfolding

The grants, announced by the university, were welcomed by Prof. Bernhard Brüne, vice president for research at Goethe University, who emphasized that the two projects address some of the most pressing questions of the present era. In his view, the current geopolitical power structures and their impact on finance, together with the rising share of neurodegenerative diseases driven by an aging population, rank among the defining challenges ahead. The ERC Starting Grant scheme is specifically designed for outstanding researchers in the early years after their doctorate, enabling them to build their own research teams and establish themselves academically with a promising project focused on fundamental principles.

The first of the two funded projects, titled GEOFINANCE—The Geopolitics of Global Finance—is led by Dr. Johannes Petry, a political scientist and research associate specializing in international relations and international political economy. Petry’s starting point is a set of questions that have moved from the margins of academic debate to the center of policy discussions worldwide: Will the financial dominance of the United States continue? Is a more strongly bipolar system emerging? Or will the global financial system become increasingly fragmented and complex? The answers, his project suggests, will shape not only markets but the distribution of power among states for decades to come.

The context for these questions is a profound transformation of the global financial world. Geopolitical rivalries, financial sanctions, investment restrictions, and deliberate efforts to reduce dependence on the US dollar are once again placing states at the center of global financial markets—a notable shift after decades in which private market actors appeared to dominate cross-border capital flows. In GEOFINANCE, Petry examines how this growing geopolitical competition is changing the relationship between states, markets, and power. Rather than treating finance as a purely technical or economic sphere, the project frames it as an arena in which political authority and market forces continuously interact and renegotiate their boundaries.

Methodologically, the project is ambitious in scope. GEOFINANCE compares key financial powers such as the United States, China, the European Union, and Japan, as well as leading international financial centers including Hong Kong, Dubai, and London. Drawing on extensive field research, newly constructed financial datasets, and network analyses, the project investigates who holds power in the global financial system and how cross-border financial networks, infrastructures, and investment flows are changing. Network analysis of this kind allows researchers to map the connections among institutions, jurisdictions, and payment and investment channels, revealing structures of dependence and influence that conventional statistics on trade or capital stocks can obscure. By combining these quantitative maps with qualitative fieldwork, the project aims to identify both the visible and the hidden architecture of financial power.

The second Starting Grant goes to the university’s faculty of medicine and addresses aging at an entirely different scale: that of the cell. Dr. Seda Koyuncu, a molecular biologist, will lead the project UbiAge—Ubiquitin Signaling as a Key Regulator of Aging and Neurodegeneration—which explores the mechanisms underlying aging and the causes of neurodegenerative diseases such as the hereditary disorder Huntington’s disease and the neuromuscular disease amyotrophic lateral sclerosis, commonly known as ALS. Both conditions are strongly associated with age and involve the progressive dysfunction and death of neurons, making the molecular events that accompany cellular aging a central target for research.

At the heart of UbiAge lies the small protein ubiquitin, a molecule whose name reflects its pervasive presence across living systems. Ubiquitin helps cells ensure that proteins are present in the right amount at the right place, and that defective proteins are sent to the cell’s own recycling system. This quality-control function, known broadly as protein homeostasis, is essential for cellular health: when the balance of protein production, modification, and degradation is disturbed, damaged or misfolded proteins can accumulate, a process widely linked to aging and to neurodegenerative disease. Koyuncu will investigate how imbalances in the cell’s protein balance reflect aging processes and contribute to the onset of neurodegenerative diseases, shedding light on the underlying mechanisms and examining how they drive the development of age-related conditions.

The project builds on a substantial body of prior evidence. Previous studies in the nematode Caenorhabditis elegans—including work by Koyuncu herself—have already shown that age-related changes in the ubiquitin system influence both lifespan and neurodegenerative processes. The transparent roundworm C. elegans is a classic model organism for aging research, prized for its short lifespan, fully mapped cell lineage, and genetic tractability, which together allow researchers to observe and manipulate the molecular events of aging in a living animal over its entire life course. With UbiAge, Koyuncu will now dissect the mechanisms behind these observations and determine how they contribute to disease, moving from correlation toward causal understanding of how ubiquitin signaling shapes the trajectory of aging in the nervous system.

Koyuncu brings seven years of postdoctoral experience in the Cologne Cluster of Excellence on Aging and Age-Associated Diseases, known as CECAD, one of Germany’s leading research centers dedicated to the biology of aging. With the ERC funding, she will now establish an independent research program at Goethe University to investigate the molecular foundations of aging and neurodegeneration. The transition from postdoctoral researcher to independent group leader is a critical juncture in a scientific career, and the ERC Starting Grant is designed precisely to make that leap possible, providing the resources to recruit a team, acquire equipment, and pursue a long-term research agenda.

Taken together, the two projects illustrate the breadth of fundamental research supported by the European Research Council, an institution established by the European Commission to fund work focused on basic principles rather than immediate applications. Petry’s GEOFINANCE project seeks to understand how geopolitical competition is redrawing the power structures of global finance, with implications for sanctions policy, currency dependence, and the stability of the international economic order. Koyuncu’s UbiAge project aims to uncover how a single, ubiquitous protein regulates the aging process and the emergence of devastating neurodegenerative diseases, with potential long-term relevance for a population in which age-related disorders are steadily increasing. Both researchers now have the opportunity, over the coming five years, to build teams and pursue questions whose answers may reshape their fields—whether the map of global financial power or the molecular clock that ticks inside every cell.

Subject of Research: ERC Starting Grant projects on the geopolitics of global finance and ubiquitin signaling in aging and neurodegeneration

Article Title: Two ERC starting grants for research projects at Goethe University

Article References: Two ERC starting grants for research projects at Goethe University. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: ERC Starting Grant, Goethe University Frankfurt, global finance, geopolitics, US dollar, financial centers, ubiquitin, aging, neurodegeneration, Huntington's disease, ALS, Caenorhabditis elegans

The technical foundation for this shift in perspective comes from systems biology. By mining curated interaction databases such as STRING and BioGRID and visualizing the results in network analysis platforms like Cytoscape, researchers have assembled maps of the molecular relationships that mutant huntingtin disturbs. Rather than a single linear pathway from misfolded protein to cell death, these maps reveal interconnected modules whose failure propagates through the cell. Crucially, the analysis identifies hub proteins—highly connected nodes such as the molecular chaperone HSP70, the mitochondrial fission regulator DRP1, the inflammatory sensor NLRP3, and the autophagy-controlling transcription factor EB (TFEB)—that act as central control points linking otherwise separate pathways. When a hub fails, the damage radiates outward along many edges at once.

One of the clearest cascades described in the review begins with the ubiquitin-proteasome system, the cell’s primary machinery for shredding damaged or misfolded proteins. Mutant huntingtin impairs this system, so damaged proteins and organelles accumulate. The resulting burden drives mitochondrial oxidative stress: reactive oxygen species rise, ATP production falters, and damaged mitochondria release danger signals. Those signals activate the NLRP3 inflammasome, a multi-protein immune complex best known for igniting inflammation in immune cells. In the Huntington’s brain, chronic NLRP3 activation sustains microglial and astrocyte inflammatory responses, which in turn erode synaptic function. The end point of this cascade is the selective degeneration of medium spiny neurons in the striatum, the cell population whose loss produces the disease’s characteristic uncontrolled movements, psychiatric disturbances, and cognitive decline.

Proteostasis—the cell’s overall management of protein folding, trafficking, and degradation—emerges as a second major battleground. Beyond the ubiquitin-proteasome system, the review details how the autophagy-lysosomal pathway, the cell’s bulk recycling route, is compromised in Huntington’s disease. TFEB, the master transcriptional regulator of lysosomal and autophagy genes, sits at a critical node here; when its activity is suppressed, neurons cannot clear aggregates or damaged mitochondria efficiently. The endoplasmic reticulum adds another layer, with ER stress and ER-mitochondrial crosstalk amplifying the damage. Recent work on polyglutamine-mediated ribotoxicity suggests that the expanded protein tract disrupts proteostasis and stress responses even at the ribosome, meaning the folding crisis begins early in the protein’s life, long before visible aggregates form.

Mitochondrial dysfunction deserves particular attention because it connects nearly every other module in the network. Studies in patient-derived fibroblasts show compromised mitochondrial organization and structure, while DRP1, the dynamin-related protein that governs mitochondrial fission, is dysregulated in the disease. Broken fission-fusion balance means damaged mitochondria cannot be segregated and removed by mitophagy, the specialized autophagy of organelles. Energy metabolism collapses as a result, with the AMP-activated protein kinase and PGC1-alpha regulatory axes—both central to cellular energy sensing—falling out of tune. The review also highlights emerging cell-death mechanisms such as ferroptosis, an iron-dependent form of lipid peroxidation-driven death that links oxidative stress, mitochondria, and the selective vulnerability of striatal neurons.

Perhaps the most consequential claim in the review is temporal: faulty neuroplasticity develops before visible protein aggregates appear. Evidence from the R6/2 and YAC128 transgenic mouse models, from neurons derived from human induced pluripotent stem cells, and from multi-omics studies indicates that synaptic transmission and plasticity are impaired early in the disease course. Brain-derived neurotrophic factor, a growth factor critical for striatal neuron survival whose transport depends on normal huntingtin, is dysregulated long before overt neurodegeneration. RNA granules and RNA-binding proteins such as muscleblind-like protein 1 and ataxin-2 add further early-stage complexity, tying the mutant protein to defects in local translation at synapses. This early dysfunction reframes the therapeutic window: interventions may need to start decades before symptoms, targeting network imbalances rather than waiting to dissolve aggregates.

The network view also explains why genetic modifiers matter so much. Beyond the CAG repeat length, which only partially predicts age of onset, genome-wide studies have identified modifier genes concentrated in DNA repair and interaction-network hubs. Hyperbolic mapping of the protein interaction network and dynamic profiling of huntingtin’s interactions in the striatum have both pointed to candidate modifiers whose normal function buffers the network against the mutant protein’s perturbations. In this framing, disease severity reflects not just the toxic protein but the resilience—or fragility—of the surrounding interaction web, which varies between individuals and shifts with age.

Therapeutically, the review surveys strategies that target the hubs rather than the aggregate itself. Chaperone-based approaches aim to boost HSP70 and the heat shock response governed by HSF1. Selective NLRP3 inflammasome inhibitors have shown neuroprotection in transgenic mouse models, and modulation of the cGAS-STING innate immune pathway represents a newer anti-inflammatory frontier. TFEB activation and small molecules that engage the autophagy-lysosomal pathway, including a p75NTR modulator that reduced huntingtin aggregates in cellular and mouse models, aim to restore cellular clearance. Mitochondria-targeted strategies, from coenzyme Q10 supplementation to compounds that modulate mTORC1 and AMPK/SIRT1/ULK1 signaling, attempt to repair the energy backbone. Epigenetic therapies, notably histone deacetylase inhibitors such as suberoylanilide hydroxamic acid, target the transcriptional dysregulation that silences protective genes.

The most ambitious interventions aim at the source. Antisense oligonucleotides designed to lower mutant huntingtin production have moved from design into clinical testing, while adeno-associated virus-mediated gene therapy approaches are advancing rapidly. The review notes that these nucleic-acid strategies could be combined with network-targeting small molecules, attacking the disease at both its genetic origin and its downstream systems-level consequences. Repurposed drugs, including the tetracycline antibiotic minocycline for its anti-inflammatory effects, and natural compounds such as resveratrol and morin that activate autophagy and antioxidant pathways, illustrate the breadth of the current pipeline.

What makes this review significant is not a single discovery but a change in the map. Huntington’s disease, on this evidence, is a network disorder in which a single expanded protein destabilizes chaperones, proteasomes, mitochondria, inflammasomes, synapses, and chromatin simultaneously—and the hubs that tie these systems together, HSP70, DRP1, NLRP3, and TFEB, are the most promising points of intervention. The authors caution that no datasets were newly generated in their analysis; it is a synthesis, and its power lies in connecting dots across mouse models, human stem-cell systems, and omics data. If the network view holds up in clinical testing, the future of Huntington’s therapy may lie not in one miracle molecule but in combination treatments that hold the entire web together, started early enough to matter.

Subject of Research: Protein-protein interaction networks in Huntington's disease pathogenesis and therapy

Article Title: Uncovering hidden protein networks in Huntington’s disease: implications for pathogenesis and therapy

Article References: Panwar, C., Goel, F., & Garg, V. K. (2026). Uncovering hidden protein networks in Huntington’s disease: implications for pathogenesis and therapy. Molecular Biology Reports, 53(1), Article 1626. https://doi.org/10.1007/s11033-026-12823-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12823-6

Keywords: Huntington's disease, mutant huntingtin, protein-protein interaction networks, proteostasis, ubiquitin-proteasome system, autophagy, mitochondrial dysfunction, NLRP3 inflammasome, neuroinflammation, synaptic dysfunction, TFEB, gene therapy

The technical foundation of this story lies in how the brain handles carbon and energy. Neurons are voracious consumers of glucose, and under aerobic conditions glycolysis converts glucose to pyruvate, which is then imported into mitochondria and oxidized by the tricarboxylic acid cycle. When oxygen is scarce or demand outpaces oxidative capacity, lactate dehydrogenase converts pyruvate to lactate, regenerating NAD+ so glycolysis can continue. In the brain, this is not merely an emergency fallback. The astrocyte-neuron lactate shuttle describes a division of labor in which astrocytes, which take up glucose and glutamate from the synaptic environment, export lactate through monocarboxylate transporters for neurons to oxidize as fuel. A complementary intracellular lactate shuttle moves lactate into mitochondria via mitochondrial monocarboxylate transporters, where it can be reconverted to pyruvate and fed into oxidative phosphorylation. The result is a metabolically flexible network in which lactate flows between cell types and compartments as both fuel and signal.

What transformed lactate from fuel to regulator was the discovery in 2019 that lactate can covalently modify lysine residues on histones—the proteins around which DNA is wound—in a reaction termed lactylation. Histone lactylation requires lactyl-coenzyme A as the acyl-donor, and the addition of a lactyl group to lysine residues alters chromatin accessibility, generally opening DNA and promoting gene transcription. This places lactylation alongside acetylation and methylation as an epigenetic mark, but with a crucial difference: its abundance tracks directly with metabolic state. When glycolysis is high and lactate accumulates, lactylation rises; when lactate falls, the mark recedes. Metabolism is thereby coupled to gene expression through a single chemical handle, and the review emphasizes that this coupling is now being mapped in detail across the nervous system.

In neural stem cells and neural progenitor cells, histone lactylation appears to be a molecular throttle on the decision to proliferate and differentiate. The review describes evidence that elevated lactate promotes the expression of genes associated with neural stem cell proliferation and neuronal maturation, including activity-regulated cytoskeletal-associated protein and brain-derived neurotrophic factor, through lactylation-driven epigenetic activation. In the adult brain, neurogenesis persists in two niches: the subgranular zone of the dentate gyrus in the hippocampus and the subventricular zone lining the lateral ventricles. Adult hippocampal neurogenesis, in particular, underpins learning, memory, and mood regulation, and markers such as doublecortin flag the newborn neurons it produces. By linking glycolytic flux to the chromatin state of neural stem cells, lactylation provides a mechanism by which the metabolic environment of the niche—oxygen tension, vascular supply, inflammatory tone—can be translated into instructions about whether progenitors stay quiescent, divide, or commit to a neuronal fate.

Lactylation is not confined to histones. Non-histone proteins, including enzymes, structural proteins, and signaling molecules, carry lysine lactylation marks that can alter their activity, stability, localization, or interaction partners. The review highlights that non-histone lactylation regulates specific protein functions in ways that extend the modification’s influence well beyond gene regulation, though the precise functional consequences at individual sites remain an active area of investigation. Because lactylation, like acetylation, adds a bulky, negatively charged group to lysine, it can compete with or mimic other modifications, creating a dense regulatory cross-talk in which metabolic state reshapes the entire post-translational modification landscape of a cell.

The protective face of lactate in the nervous system rests on three pillars described in the review. First, lactate is an efficient energy substrate for neurons, and supporting neuronal metabolism can buffer cells against the energetic stress that accompanies aging and disease. Second, lactate signaling promotes neurotrophic effects: lactate can stimulate vascular endothelial growth factor A production, supporting the vascular niche that nourishes neural progenitors, and it engages hydroxycarboxylic acid receptor 1, a G-protein-coupled receptor that mediates anti-inflammatory signaling. Third, lactate can dampen neuroinflammation. In models of activated immune cells, elevated lactate has been shown to shift macrophage and microglial behavior toward less inflammatory phenotypes, in part through lactylation-dependent and HCAR1-dependent pathways. In the context of neurodegeneration, where chronic inflammation and mitochondrial dysfunction are hallmarks, these mechanisms suggest that boosting lactate availability or lactylation could, in principle, slow neuronal loss.

The toxic face emerges when the same chemistry is applied in the wrong context. The review is explicit that the switch between protection and harm depends on concentration, cell type, pathological setting, and the specific lactylation site involved. Excessive lactate accumulation accompanies the acidic, hypoxic conditions of injury and chronic disease, where it can exacerbate oxidative damage and support inflammatory programs. In neurodegenerative diseases characterized by protein aggregation—amyloid-beta and tau in Alzheimer’s disease, alpha-synuclein in Parkinson’s disease, huntingtin in Huntington’s disease—altered post-translational modification landscapes may influence how proteins misfold, aggregate, and evade clearance. Lactylation of proteins involved in aggregation or in the machinery that clears misfolded proteins could tip the balance toward pathology. Similarly, in amyotrophic lateral sclerosis, where motor neuron degeneration is coupled to defects in the motor neuron lactate shuttle and disrupted energy metabolism, the direction of lactate flux may determine whether supporting cells nourish or starve the vulnerable neurons they surround.

The disease-specific evidence reviewed by the authors paints a picture of context-dependence rather than simple causation. In Alzheimer’s disease, impaired glucose metabolism and reduced lactate handling are observed alongside amyloid precursor protein pathology, and altered lactate dynamics in the cerebrospinal fluid reflect broader metabolic decline; yet lactate’s neurotrophic and anti-inflammatory actions suggest potential benefit if delivered appropriately. In Parkinson’s disease, dopaminergic neurons in the substantia nigra are energetically fragile, with high mitochondrial demand and susceptibility to reactive oxygen species, making metabolic support attractive but also raising the stakes of any intervention that perturbs redox balance. In Huntington’s disease, mutant huntingtin disrupts transcription and metabolism broadly, and lactylation-dependent gene regulation could either compensate for or compound these defects. The unifying insight is that lactate is not simply good or bad; it is a dose-, timing-, and site-dependent variable that must be read in the context of each disease stage and cellular environment.

Therapeutic implications follow directly from this framing, and the review evaluates several strategies for manipulating lactate metabolism and lactylation. Approaches include modulating lactate dehydrogenase activity, targeting monocarboxylate transporters to redirect lactate flux between cells, pharmacologically shifting metabolism with agents such as dichloroacetate that favor mitochondrial oxidation over glycolysis, and exploiting exercise—high-intensity interval training elevates circulating lactate and has been associated with enhanced neurotrophic signaling and adult hippocampal neurogenesis. Enzymes that write and erase lysine lactylation marks are also candidate drug targets, analogous to the histone acetyltransferases and deacetylases that have yielded epigenetic therapies in oncology. The challenge, as the authors stress, is achieving the right modification at the right site in the right cells: systemic manipulation of lactate would simultaneously affect neurons, astrocytes, microglia, endothelial cells, and peripheral immune cells, each of which may respond differently.

The review’s conclusion is a call for precision rather than enthusiasm. Lactate and protein lactylation exhibit a genuine regulatory duality in neurogenesis and neurodegenerative disease, and the factors that determine which face prevails—concentration, cell type, pathological context, and lactylation site—are only beginning to be mapped. Site-specific mapping of the lactylome in human disease tissue, tools for cell-type-selective manipulation of lactylation, and biomarkers that report on lactylation state in living patients are among the needs the authors identify for clinical translation. If those gaps close, the molecule once dismissed as metabolic exhaust may become a lever for regenerating the aging and diseased brain—one lysine residue at a time.

Subject of Research: Roles of lactate metabolism and lysine lactylation in adult neurogenesis and neurodegenerative disease

Article Title: Roles of lactate and protein lactylation in neurogenesis and neurodegenerative disease

Article References: Zhou, X., Han, J., Cui, X., Wu, S., Lu, Z., & Zong, S. (2026). Roles of lactate and protein lactylation in neurogenesis and neurodegenerative disease. Journal of Translational Medicine, 24(1), Article 1210. https://doi.org/10.1186/s12967-026-08940-2

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08940-2

Keywords: lactate, protein lactylation, neurogenesis, neural stem cells, epigenetics, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, astrocyte-neuron lactate shuttle, histone modification, neuroinflammation

Huntington’s disease is a relentlessly progressive neurodegenerative disorder caused by an expanded CAG repeat in the Huntingtin gene, which produces a mutant protein that accumulates in neurons and exerts a toxic gain of function. The hallmark motor symptom, chorea, consists of involuntary, irregular movements that grow more severe over time and often interfere with daily activities. But the disease extends far beyond movement. Patients face progressive cognitive decline and a heavy burden of psychiatric symptoms, including anxiety and depression, with roughly twenty percent experiencing suicidal ideation. No preventive or disease-modifying therapy exists, so treatment remains purely symptomatic, and the pharmacological toolkit is thin.

The current standard of care for chorea rests on inhibitors of the vesicular monoamine transporter type 2, or VMAT2, a protein that packages monoamine neurotransmitters into synaptic vesicles. By blocking this transporter, drugs such as tetrabenazine, deutetrabenazine, and valbenazine deplete presynaptic dopamine, dampening the excess dopaminergic tone that drives chorea. This mechanism makes physiological sense: in Huntington’s disease, elevated presynaptic dopamine coincides with reduced postsynaptic D1 and D2 receptor expression on striatal neurons, so reducing dopamine release addresses the core imbalance more directly than postsynaptic dopamine receptor blockers like antipsychotics. Yet the same dopamine depletion carries a steep price. These drugs can precipitate or worsen depression, suicidality, akathisia, parkinsonism, and somnolence, and tetrabenazine carries a black box warning in the United States and is contraindicated in patients with depression or suicidal ideation in Europe.

SOM3355 emerged from an unusual route. SOM Biotech, the Spanish company behind the drug, identified bevantolol hydrochloride, a mild beta-1 blocker with thirty years of clinical use and cumulative exposure in more than 2.5 million people, through its proprietary artificial intelligence platform SOMAI PRO as a VMAT2 inhibitor. Subsequent pharmacological characterisation revealed a profile that distinguishes it from tetrabenazine in three ways. Its interaction with the VMAT2 binding site differs, producing monoamine signalling changes with a similar effect on dopamine but a significantly weaker effect on serotonin, roughly ten-fold lower serotonin affinity than tetrabenazine. It also inhibits VMAT1, a transporter tetrabenazine does not touch, and it retains beta-1 adrenergic blockade, a property that lipophilic beta-blockers have used to treat anxiety, irritability, agitation, memory disorders, and akathisia in other neuropsychiatric conditions.

The SOMCT03 trial was designed to test whether this polypharmacology translates into clinical benefit. It was a double-blind, randomised, placebo-controlled, dose-ranging study in which adults with genetically confirmed Huntington’s disease and a baseline Total Maximal Chorea score of at least ten were allocated in a one-to-one-to-one ratio to SOM3355 400 mg per day, SOM3355 600 mg per day, or placebo. The primary endpoint was the change in Total Maximal Chorea score, measured on the Unified Huntington’s Disease Rating Scale, between baseline and the end of the maintenance dose period, analysed with a mixed-effect model for repeated measures. The trial also broke new ground by incorporating Huntington’s-specific safety endpoints, including the Problem Behaviour Assessment-short form for behavioural symptoms, alongside scales for depression, sleepiness, and akathisia, aiming to define the drug’s profile beyond chorea alone.

The headline result was complicated by a phenomenon familiar to anyone who follows clinical trials: a strikingly strong placebo response. In the full modified intention-to-treat population, neither dose separated significantly from placebo on the primary endpoint, with the 600 mg per day dose showing a least-squares mean difference of minus 1.0 points and the 400 mg dose minus 0.2 points. Placebo patients improved by up to 2.3 points, roughly twice what the investigators had anticipated, possibly reflecting expectation effects and the unusually extensive contact with healthcare professionals in a disease with few effective treatments available in Europe.

However, the picture changed in the predefined sensitivity analysis restricted to the 122 patients, eighty-eight percent of the cohort, who were not taking concomitant antipsychotics, which act as dopamine receptor blockers and confound the assessment of any dopaminergic agent. In this subgroup, the 600 mg per day dose achieved a statistically significant reduction in chorea compared with placebo, with a least-squares mean difference of minus 1.3 points. A post-hoc analysis of the 57 patients who were both antipsychotic-free and had baseline chorea scores above twelve, corresponding to the upper mild range and more comparable to populations in other VMAT2 inhibitor trials, showed an even stronger effect, with chorea scores falling by 4.5 points at the final on-treatment visit and a placebo-adjusted difference of minus 1.8 points. These figures sit comfortably alongside the phase 3 results for valbenazine and deutetrabenazine, which produced placebo-adjusted differences of minus 3.2 and minus 2.5 points respectively.

Crucially, the numeric improvements were echoed by global clinical impressions. On the Clinical Global Impression of Change, seventy percent of patients on 400 mg per day and fifty-six percent on 600 mg per day were rated as improved at the final visit, compared with thirty-seven percent on placebo, and in the antipsychotic-free subgroup with higher baseline chorea, seventy-four percent of patients on the higher dose were rated improved versus twenty-one percent on placebo. Patient-rated impressions told the same story. The investigators argue that this convergence between score reductions and validated global measures of real-world change demonstrates that the observed effects are clinically meaningful to both patients and physicians, a point they intend to address directly in the design of the upcoming phase 3 study.

The safety findings may prove to be the trial’s most consequential contribution. Eighty-four percent of participants completed the study, most adverse events were mild and judged unrelated to treatment, and there were no deaths. The most notable drug-related event was bradycardia, an expected consequence of beta-1 blockade, reported in twelve percent of patients on the higher dose and leading to discontinuation in a handful of cases; heart rate reduction plateaued at around fifteen beats per minute at the 400 mg dose with no further decline at 600 mg. Blood pressure changes remained within normal limits and no QT interval prolongation was observed. More striking was what did not happen: no suicidality or suicide attempts occurred on the Columbia-Suicide Severity Rating Scale among drug-treated patients, the Beck Depression Inventory score actually fell by three points in the 600 mg arm, the Epworth Sleepiness and Montreal Cognitive Assessment scales showed no negative effects, and the Barnes Akathisia Rating Scale detected no emergence of akathisia in any group. The behavioural assessment even hinted at mild improvements in anxiety, apathy, and certain abnormal behaviours.

The trial has limitations the authors acknowledge candidly. Concomitant antipsychotic use confounded the primary analysis, the final visit assessments in the high-dose arm were performed during dose down-titration at lower plasma concentrations, the largely white European cohort limits generalisability, and the protocol did not follow sex and gender equity reporting guidelines. Still, the overall picture is of a drug that matches existing VMAT2 inhibitors on chorea control in the patients most relevant to such treatment, while eliminating the psychiatric and motor liabilities that constrain current therapy. A double-blind, placebo-controlled phase 3 study of SOM3355 at 600 mg per day is planned to confirm efficacy and long-term safety across the disease course. If it succeeds, a fifty-year-old antihypertensive, resurrected by an algorithm, could become the first chorea treatment that Huntington’s patients can take without trading away their mood, their sleep, or their peace of mind.

Subject of Research: A phase 2b trial of the repurposed beta-blocker SOM3355 for treating chorea in Huntington's disease

Article Title: Safety and efficacy of SOM3355 in patients with Huntington’s disease (SOMCT03): a phase 2b, randomised, placebo-controlled, multicentre, dose-ranging study

Article References: Kulisevsky, J., Craufurd, D., Lewerenz, J., Scaglione, C., Squitieri, F., Youssov, K., Burgunder, J.-M., Ferré, A., Panigone, S., & Medori, R. (2026). Safety and efficacy of SOM3355 in patients with Huntington’s disease (SOMCT03): a phase 2b, randomised, placebo-controlled, multicentre, dose-ranging study. eClinicalMedicine, 100, Article 104234. https://doi.org/10.1016/j.eclinm.2026.104234

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104234

Keywords: Huntington's disease, chorea, SOM3355, bevantolol, VMAT2 inhibitor, drug repurposing, clinical trial, neurodegeneration, psychiatric safety, phase 2b, tetrabenazine, artificial intelligence drug discovery

The logic of the discovery begins with Huntington’s disease itself. The disorder is caused by an abnormal expansion of CAG trinucleotide repeats in the Huntingtin gene, which encodes an elongated poly-glutamine tract at the beginning of the protein. This expanded stretch drives misfolding, and the misfolded protein forms aggregates that disrupt transcription, intracellular transport, metabolism and, crucially, the ubiquitin-proteasome system, the cellular machinery responsible for shredding damaged or unwanted proteins. In patients, the chymotrypsin-like and caspase-like activities of the proteasome are measurably reduced in the striatum and cortex, the very brain regions that atrophy as the disease progresses. Eliminating the aggregates, therefore, has long been considered one of the most promising directions for therapy, but the question of how to do it safely has remained open.

MicroRNAs offered a tantalizing lead. These short non-coding RNAs regulate gene expression by binding to the 3′ untranslated regions of target messenger RNAs, blocking translation and thereby suppressing protein production. In the central nervous system, they tune everything from neurotransmitter receptors to ion channels, and several have documented neuroprotective effects in stroke, Alzheimer’s and Parkinson’s models. miR-196a had already earned attention in Huntington’s research: previous work from the same group showed that it improves neuronal morphology through the RANBP10 and IGF2 pathways, exerts antioxidant effects via the USP15/NRF2 axis, and, most strikingly, reduces mutant huntingtin aggregates and rescues pathological phenotypes in cell, mouse and induced pluripotent stem cell models. Yet the huntingtin gene contains no miR-196a binding sites, leaving the mechanism behind the aggregate reduction a genuine mystery.

To solve it, the team turned to unbiased proteomics. They transfected mouse neuroblastoma N2a cells with a fluorescent mutant huntingtin fragment containing 84 glutamine repeats, together with either miR-196a or a irrelevant control microRNA, and then analyzed the entire proteome by liquid chromatography-tandem mass spectrometry. Of 2,681 proteins identified, 147 rose and 144 fell significantly in the miR-196a-treated cells. Applying progressively stricter fold-change cutoffs and intersecting the results with five independent microRNA target-prediction databases, the researchers narrowed the field to six candidates. Western blot validation confirmed that two of them, Rad23b and Snap91, were significantly downregulated by miR-196a, and Rad23b, with its known ties to proteasome function, became the focus.

Confirming direct regulation came next. The researchers cloned the 3′ untranslated region of Rad23b downstream of a luciferase reporter and showed that miR-196a markedly suppressed luciferase activity, an effect abolished when the predicted binding site was mutated. The relationship held in living animals as well: cerebral cortex from miR-196a transgenic mice showed a moderate but significant reduction in Rad23b protein. Meanwhile, analysis of a public RNA sequencing dataset from directly reprogrammed striatal neurons revealed that Rad23b mRNA was significantly elevated in neurons derived from symptomatic Huntington’s patients compared with presymptomatic carriers, hinting that Rad23b tracks with disease progression rather than merely correlating with the mutation itself.

The functional experiments that followed delivered the study’s central surprise. When the researchers overexpressed Rad23b alongside mutant huntingtin in N2a cells, aggregates flourished, both the insoluble clumps and the soluble protein rose on Western blots, and cell death, measured by propidium iodide staining, climbed significantly. Conversely, knocking Rad23b down with short hairpin RNA or deleting it entirely using CRISPR-Cas9 shrank the aggregates dramatically. The effect was not an artifact of the fluorescent tag: untagged mutant huntingtin behaved the same way. When Rad23b was reintroduced into cells already treated with miR-196a, the microRNA’s suppressive effect on aggregates was reversed, establishing Rad23b as a key mediator of miR-196a’s neuroprotection.

Structural dissection explained how Rad23b physically engages the toxic protein. Fluorescently tagged Rad23b formed puncta that colocalized with huntingtin aggregates in cultured cells, and endogenous Rad23b did the same in the cortex and striatum of Huntington’s transgenic mice, while remaining evenly distributed in healthy animals. Co-immunoprecipitation confirmed a direct physical interaction in both directions. Mutating any of the three lysine residues at positions 6, 9 and 15 in the N-terminus of huntingtin, the likely sites of ubiquitination, reduced the Rad23b-driven aggregation, and deleting both of Rad23b’s ubiquitin-associated domains abolished its effect, pinpointing the ubiquitin-binding machinery as the critical interface.

The mechanism, however, turned out to be darker than a simple shuttle-to-destruction story. Rad23b is classically described as an ubiquitin shuttle protein, using its ubiquitin-like domain to dock at the proteasome and its ubiquitin-associated domains to ferry ubiquitinated cargo for degradation. Consistent with that role, Rad23b overexpression increased the ubiquitination of mutant huntingtin. Yet the ubiquitinated protein was not destroyed. A reporter assay using a destabilized GFP substrate revealed that Rad23b-deficient cells degraded proteasomal cargo faster than wild-type cells, and direct enzymatic measurements showed that deleting Rad23b significantly boosted the chymotrypsin-like activity of the proteasome, the very activity that is depressed in the brains of Huntington’s patients. Inhibiting the proteasome with MG132 restored aggregates in Rad23b-knockout cells, whereas blocking autophagy with chloroquine had no effect, confirming that the pathway in play is the ubiquitin-proteasome system, not autophagy. In short, Rad23b tags huntingtin for destruction but simultaneously gums up the destruction machinery, a molecular sabotage that tips the balance toward accumulation.

The in vivo evidence sealed the case. The team generated Rad23b transgenic mice by lentiviral transgenesis and crossed them with R6/2 Huntington’s mice, which carry an N-terminal human huntingtin fragment with 120 to 150 CAG repeats. The resulting double-transgenic animals fared measurably worse than their Huntington’s littermates: at eight and nine weeks of age they fell off an accelerating rotarod sooner and at lower speeds, and they showed elevated hindlimb clasping scores, a classic sign of worsening motor dysfunction. Biochemical analysis of the cortex at six weeks revealed significantly more mutant huntingtin aggregates in the double transgenics, and immunofluorescent staining of the retrosplenial cortex showed Rad23b-labeled aggregates accompanied by significantly more TUNEL-positive dying cells. Neither Rad23b nor miR-196a transgene expression alone produced any Huntington-like pathology, underscoring that Rad23b acts by amplifying the mutant protein’s toxicity rather than causing disease on its own.

The implications reach beyond Huntington’s disease. Rad23b has been found sequestered in neuronal inclusions across a striking range of disorders, including spinocerebellar ataxias, frontotemporal dementia, amyotrophic lateral sclerosis and Parkinson’s disease, yet its role appears context-dependent: in C9ORF72-linked disease, restoring Rad23b actually reduces poly-glycine-alanine aggregates. The authors suggest their mechanism fits poly-glutamine aggregates specifically, and they caution that bulk cortical lysates may dilute neuron-specific proteasomal changes, that behavioral testing here focused on motor readouts, and that miR-196a likely acts through multiple pathways, including metabolic ones hinted at by their proteomic enrichment analyses. Even so, the conclusion is compelling: downregulating Rad23b, or disrupting its interaction with mutant huntingtin, offers a concrete, mechanistically grounded strategy to clear toxic aggregates and slow disease progression, potentially applicable across the family of poly-glutamine disorders. For a disease that has resisted every therapeutic attempt for decades, a small RNA with a well-defined target is exactly the kind of lead the field has been waiting for.

Subject of Research: miR-196a-mediated suppression of Rad23b to reduce mutant huntingtin aggregates through the ubiquitin-proteasome system in Huntington's disease

Article Title: miR-196a reduces mutant Huntingtin aggregates by Rad23b-mediated degradation in Huntington’s disease

Article References: Tung, C.-W., Chan, S. C., Chen, Y.-C., Wu, P.-M., Cheng, P.-H., Chen, C.-M., & Yang, S.-H. (2026). miR-196a reduces mutant Huntingtin aggregates by Rad23b-mediated degradation in Huntington’s disease. Journal of Biomedical Science, 33(1), Article 90. https://doi.org/10.1186/s12929-026-01292-5

Image Credits: AI Generated

DOI: 10.1186/s12929-026-01292-5

Keywords: Huntington's disease, miR-196a, Rad23b, mutant huntingtin, protein aggregates, ubiquitin-proteasome system, microRNA, neurodegeneration, proteomics, R6/2 transgenic mice, chymotrypsin-like activity, gene regulation

One of the most striking conceptual advances came from Paola Scaffidi of the European Institute of Oncology in Italy, who introduced a systems-level framework for understanding epigenetic regulation in cancer. She described the epigenetic regulatory network, or ERN, as the collective assembly of epigenetic modifications that drive cellular states, with individual regulators ranging from dispensable to absolutely essential for cell survival. In healthy cells, this network is built with substantial functional redundancy, so the loss of one or a few components is generally tolerated through compensatory mechanisms. But when oncogenic drivers are added to the mix, the network becomes fragile. Scaffidi presented evidence that cancer cells globally lose roughly 30 percent of their epigenetic regulators, producing aberrant transcriptional responses to stress and an enhanced adaptive capacity compared with normal cells. Many of these losses are subclonal and take on stage-specific roles as tumours evolve, a finding that reframes epigenetic instability not simply as collateral damage but as a potential vulnerability that therapies could exploit.

Chromatin dynamics occupied centre stage throughout the meeting. Karl Ekwall of the Karolinska Institute in Sweden explored how chromatin-modifying enzyme complexes govern cell cycle kinetics in yeast and human fibroblast models, identifying these complexes as essential regulators of quiescence induction when cells face nutrient deprivation. Notably, in vitro analyses showed that targeting these complexes with ouabain, an inhibitor of the LEO1 component, altered LEO1 expression in tumour models but not in normal human fibroblasts, hinting at a therapeutic window for oncology. Geneviève Almouzni of the Curie Institute in France closed the conference with a keynote on chromatin integrity and histone variants, explaining how the replicative histone H3.1, enriched at late-replicating regions, and the variant H3.3, enriched at actively transcribed early-replicating regions, demarcate replication initiation zones with remarkable precision. Her presentation detailed how aberrant histone H3 function, whether through mutation of the protein itself or of chaperone proteins such as DAXX/ATRX, ASF1, CENP-A, HJURP and HIRA, contributes to cancer and other diseases, including evidence that restoring the chaperone HIRA can rescue defective H3.3 deposition patterns.

Cancer epigenetics featured prominently, with complementary sessions probing histone mutations, DNA methylation, transcription factors, chromatin topology and even the tumour microbiome. Jonathan Licht of the University of Florida described the contribution of histone fold mutations, which a pan-cancer analysis found in approximately 7 percent of patients, particularly in bladder, oesophageal, head and neck, and skin cancers. The most common of these, H2B E76K, destabilises the H2B/H4 interface, accelerating chromatin degradation into oligonucleosomes and freeing H2A-H2B dimers from the histone octamer. In lung epithelial cell models, this opens up chromatin and ramps up signalling through polycomb-repressed regions, epithelial-mesenchymal transition pathways, and AKT and c-Jun cascades, all of which can promote migration, proliferation, cytokine secretion and resistance to apoptosis.

DNA methylation emerged as a versatile player in cancer progression and diagnosis. Aniruddha Chatterjee of the University of Otago in New Zealand presented work on colorectal cancer showing that conserved aberrations in the DNA methylome discriminate powerfully between matched primary tumours, lymph node metastases and liver metastases. This matters because metastasis drives 90 percent of cancer deaths, yet no purely genetic drivers can fully explain successful metastatic colonisation; epigenetic plasticity appears to supply the adaptability tumours need. His team is using CRISPR-dCas9-based epigenetic editing at key regulatory loci to test whether methylation changes are cause or consequence. On the translational front, early findings suggest DNA methylome profiling of cell-free DNA, combined with artificial intelligence models, could underpin liquid biopsies for colorectal cancer screening. Susan Clark of the Garvan Institute of Medical Research in Australia widened the lens to the three-dimensional genome, describing how mutations at ‘persistent’ CTCF binding sites, which anchor loops and topologically associated domain borders, recur in prostate and breast cancers and may disrupt higher-order chromatin architecture.

In one of the more unexpected twists of the meeting, Maria Rescigno of Humanitas University in Italy connected the microbiome to epigenetics in cancer. Progressive microbial deregulation accompanies tumour development, and in mouse models the loss of the bacterium Faecalibaculum rodentium was reversed by restoring the organism, which reduced tumour growth and number. Intriguingly, F. rodentium produces butyrate as it proliferates, acting as a histone deacetylase inhibitor that epigenetically modulates apoptosis. A phylogenetically similar strain is underrepresented in human advanced adenomas, and in colorectal cancer, intra-tumoural bacteria appear to modulate treatment response through soluble metabolites, or ‘postbiotics’. In the context of anti-PD-1 checkpoint blockade, different bacterial strains produce postbiotics with different effects on HLA class I expression, suggesting postbiotic therapy could help overcome treatment resistance.

Beyond cancer, the meeting showcased epigenetics in ageing and non-malignant disease. Steve Horvath of Altos Labs in the United Kingdom traced the evolution of epigenetic clocks, machine learning algorithms built on DNA methylation patterns at CpG dinucleotides that estimate chronological or biological age. First-generation clocks estimate chronological age, second-generation clocks predict clinical phenotypes and mortality risk, and third-generation clocks aim for multi-species utility. GrimAge, designed to predict time to death, showed predictive value for chronic obstructive pulmonary disease, type 2 diabetes and ischaemic heart disease over 13 years of follow-up. Andrea Fuso of Sapienza University of Rome demonstrated cross-talk between DNA methylation and non-coding RNAs in Alzheimer’s disease, where methylation modulates PSEN1 and miR-29a, which in turn targets BACE1 and the demethylase gene TET1, feeding into amyloid plaque deposition and linking B vitamin status and one-carbon metabolism to neurodegeneration.

Neurodegeneration and cardiometabolic disease drew further epigenetic links. Eran Meshorer of The Hebrew University of Jerusalem showed that organoid models of early Huntington’s disease display global hypomethylation, altered DNMT3A and DNMT3B signatures and methylation ages older than controls. Counterintuitively, the polyglutamine inclusion bodies characteristic of the disease proved protective, with aggregate-forming cells dying at one third the rate of others; the transcription factor ATF3 was implicated, since its knockout prevented inclusion body formation. Melanie Waldenberger of Helmholtz Munich and Marie Loh of Nanyang Technological University in Singapore presented epigenome-wide studies of dyslipidaemia and cardiovascular risk, respectively, both emphasising ethnic diversity. In the Singapore-based HELIOS study of roughly 50,000 adults, 1,926 CpG sites were associated with carotid intima-media thickness in Asian individuals, 91 percent of them irrelevant in European populations, with two sentinel sites showing possible causal roles, underscoring the danger of extrapolating epigenomic findings across ancestries.

The therapeutic frontier was arguably the most electrifying territory of all. José Sardina of the Josep Carreras Leukaemia Research Institute in Spain used targeted DNA methylation to hypermethylate the IL1RN promoter, generating macrophages with aberrant inflammatory responses and transcriptional profiles resembling tumour-resident macrophages. Angelo Lombardo of the San Raffaele-Telethon Institute for Gene Therapy in Italy described an all-in-one zinc finger epigenetic editor delivered by lipid nanoparticles that silenced PCSK9 in vivo for nearly a year, persisting even through liver regeneration, outperforming CRISPR-dCas9 constructs with minimal off-target effects. Related platforms are being developed for durable silencing of hepatitis B virus and, prospectively, CAG length-specific silencing in Huntington’s disease. A round table debated the roadmap to the clinic, highlighting needs for standardised delivery, early regulatory engagement, quality control and stakeholder inclusion, including patients and low- and middle-income countries.

Clinical trials and drug discovery sessions reinforced the momentum. Christophe Le Tourneau of the Curie Institute presented the PEVO basket trial of the HDAC inhibitor vorinostat combined with immunotherapy in recurrent or metastatic squamous cell carcinomas, reporting a median response rate of 26 percent, highest in anal and cervical tumours, with better responses linked to microsatellite instability, HPV positivity and high PD-L1 scores. Emily Dykhuizen of Purdue University described SWI/SNF subcomplex targeting, including BRD9 degraders showing anti-tumour activity through macrophage activation and ARID1A inhibition flipping cold tumours toward immune-infiltrated hot states. Cheryl Arrowsmith of the University of Toronto outlined chemical probe screening revealing context-dependent EZH2 vulnerabilities, while Christoph Bock of CeMM in Austria closed with a vision of epigenetic priming, in which ‘alertness drugs’ could pre-emptively harden innate immunity against infection, and of AI tools such as CellWhisperer that let researchers interrogate sequencing data in plain English. Together, the meeting made clear that epigenetics, once a purely academic curiosity, is now positioned to reshape diagnostics and therapy across medicine.

Subject of Research: Recent advances and clinical opportunities in epigenetics research presented at the 4th Clinical Epigenetics International Conference

Article Title: Clinical epigenetics: recent advances and opportunities

Article References: Smith, J., Chatterjee, A., & Rodger, E. J. (2025). Clinical epigenetics: recent advances and opportunities. Epigenetics Communications, 5(1), Article 7. https://doi.org/10.1186/s43682-025-00038-y

Image Credits: AI Generated

DOI: 10.1186/s43682-025-00038-y

Keywords: clinical epigenetics, epigenetic editing, DNA methylation, chromatin, cancer epigenetics, epigenetic clocks, epigenetic therapeutics, HDAC inhibitors, CRISPR, microbiome, Alzheimer's disease, Huntington's disease